Disease stage in Alzheimer disease and treatment effects of rivastigmine

Alexander Kurz, Martin Farlow, Peter Quarg, René Spiegel

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The efficacy and tolerability of the cholinesterase inhibitor rivastigmine in the treatment of Alzheimer disease (AD) have been demonstrated in several clinical trials, which included patients with a wide range of dementia severities. To investigate the association between severity of disease and treatment response, the combined data from three large randomized, placebo-controlled trials were analyzed. The pooled patient population was stratified into three cohorts showing moderately severe (Mini-Mental State Examination score [MMSE] ≤ 15), moderate (MMSE 16-22), and mild (MMSE ≥ 22) dementia. In each cohort, the effects of rivastigmine 6 to 12 mg/day versus placebo were evaluated using the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-cog) and the Progressive Deterioration Scale. Rivastigmine 6 to 12 mg/day maintained ADAS-cog scores at or above placebo levels in all cohorts, while cognitive deterioration with placebo was progressive and severity dependent. Activities of daily living showed statistically significant benefits with rivastigmine across all severity cohorts.

Original languageEnglish
Pages (from-to)123-128
Number of pages6
JournalAlzheimer Disease and Associated Disorders
Volume18
Issue number3
DOIs
StatePublished - Jul 2004

Fingerprint

Rivastigmine
Alzheimer Disease
Placebos
Dementia
Cohort Effect
Cholinesterase Inhibitors
Therapeutics
Activities of Daily Living
Randomized Controlled Trials
Clinical Trials

Keywords

  • Clinical trial
  • Rivastigmine

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Disease stage in Alzheimer disease and treatment effects of rivastigmine. / Kurz, Alexander; Farlow, Martin; Quarg, Peter; Spiegel, René.

In: Alzheimer Disease and Associated Disorders, Vol. 18, No. 3, 07.2004, p. 123-128.

Research output: Contribution to journalArticle

Kurz, Alexander ; Farlow, Martin ; Quarg, Peter ; Spiegel, René. / Disease stage in Alzheimer disease and treatment effects of rivastigmine. In: Alzheimer Disease and Associated Disorders. 2004 ; Vol. 18, No. 3. pp. 123-128.
@article{abacd12154cd415295dad0b4c0856b84,
title = "Disease stage in Alzheimer disease and treatment effects of rivastigmine",
abstract = "The efficacy and tolerability of the cholinesterase inhibitor rivastigmine in the treatment of Alzheimer disease (AD) have been demonstrated in several clinical trials, which included patients with a wide range of dementia severities. To investigate the association between severity of disease and treatment response, the combined data from three large randomized, placebo-controlled trials were analyzed. The pooled patient population was stratified into three cohorts showing moderately severe (Mini-Mental State Examination score [MMSE] ≤ 15), moderate (MMSE 16-22), and mild (MMSE ≥ 22) dementia. In each cohort, the effects of rivastigmine 6 to 12 mg/day versus placebo were evaluated using the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-cog) and the Progressive Deterioration Scale. Rivastigmine 6 to 12 mg/day maintained ADAS-cog scores at or above placebo levels in all cohorts, while cognitive deterioration with placebo was progressive and severity dependent. Activities of daily living showed statistically significant benefits with rivastigmine across all severity cohorts.",
keywords = "Clinical trial, Rivastigmine",
author = "Alexander Kurz and Martin Farlow and Peter Quarg and Ren{\'e} Spiegel",
year = "2004",
month = "7",
doi = "10.1097/01.wad.0000127445.00442.a1",
language = "English",
volume = "18",
pages = "123--128",
journal = "Alzheimer Disease and Associated Disorders",
issn = "0893-0341",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Disease stage in Alzheimer disease and treatment effects of rivastigmine

AU - Kurz, Alexander

AU - Farlow, Martin

AU - Quarg, Peter

AU - Spiegel, René

PY - 2004/7

Y1 - 2004/7

N2 - The efficacy and tolerability of the cholinesterase inhibitor rivastigmine in the treatment of Alzheimer disease (AD) have been demonstrated in several clinical trials, which included patients with a wide range of dementia severities. To investigate the association between severity of disease and treatment response, the combined data from three large randomized, placebo-controlled trials were analyzed. The pooled patient population was stratified into three cohorts showing moderately severe (Mini-Mental State Examination score [MMSE] ≤ 15), moderate (MMSE 16-22), and mild (MMSE ≥ 22) dementia. In each cohort, the effects of rivastigmine 6 to 12 mg/day versus placebo were evaluated using the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-cog) and the Progressive Deterioration Scale. Rivastigmine 6 to 12 mg/day maintained ADAS-cog scores at or above placebo levels in all cohorts, while cognitive deterioration with placebo was progressive and severity dependent. Activities of daily living showed statistically significant benefits with rivastigmine across all severity cohorts.

AB - The efficacy and tolerability of the cholinesterase inhibitor rivastigmine in the treatment of Alzheimer disease (AD) have been demonstrated in several clinical trials, which included patients with a wide range of dementia severities. To investigate the association between severity of disease and treatment response, the combined data from three large randomized, placebo-controlled trials were analyzed. The pooled patient population was stratified into three cohorts showing moderately severe (Mini-Mental State Examination score [MMSE] ≤ 15), moderate (MMSE 16-22), and mild (MMSE ≥ 22) dementia. In each cohort, the effects of rivastigmine 6 to 12 mg/day versus placebo were evaluated using the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-cog) and the Progressive Deterioration Scale. Rivastigmine 6 to 12 mg/day maintained ADAS-cog scores at or above placebo levels in all cohorts, while cognitive deterioration with placebo was progressive and severity dependent. Activities of daily living showed statistically significant benefits with rivastigmine across all severity cohorts.

KW - Clinical trial

KW - Rivastigmine

UR - http://www.scopus.com/inward/record.url?scp=4444229993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444229993&partnerID=8YFLogxK

U2 - 10.1097/01.wad.0000127445.00442.a1

DO - 10.1097/01.wad.0000127445.00442.a1

M3 - Article

C2 - 15494617

AN - SCOPUS:4444229993

VL - 18

SP - 123

EP - 128

JO - Alzheimer Disease and Associated Disorders

JF - Alzheimer Disease and Associated Disorders

SN - 0893-0341

IS - 3

ER -